Related Experiment Video
Updated: Jan 17, 2026
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
Enhancing the sensitivity of lung adenocarcinoma to immune therapeutic agents through SPRED1
Chen Wu1, Lingling Ma1, Yi Wang1
1Department of Science and Education, Affiliated Maternity and Child Health Care Hospital of Nantong University, Nantong, China.
Background:
Programmed death-ligand 1 (PD-L1), a classic immune checkpoint, is a key target for immunotherapy. Research has demonstrated that Sprouty-related EVH1 domain-containing 1 (SPRED1), a negative regulator of the mitogen-activated protein kinase (MAPK) pathway, modulates PD-L1 expression and exhibits antitumor activity in diverse cancers. This study aimed to investigate the role and mechanisms of SPRED1 in enhancing the sensitivity of lung adenocarcinoma (LUAD) to immunotherapy and develop novel clinical therapeutic sensitization strategies.
Methods:
In this study, bioinformatics technologies were employed to examine the interaction between SPRED1 and the survival prognosis of patients with LUAD and to identify key interacting molecules of SPRED1. The expression levels of SPRED1 in LUAD tissues were measured by tissue staining, Western blotting, and quantitative real-time polymerase chain reaction (qRT-PCR). Kaplan-Meier analysis was used to confirm the correlation between SPRED1 and the prognosis of patients with LUAD. Moreover, Cell Counting Kit-8 (CCK-8), colony formation, wound healing, and Transwell assays were conducted to investigate the effects of SPRED1 on LUAD cell function and immunotherapy.
Results:
Bioinformatics analyses revealed that SPRED1 had a low expression in patients with LUAD and was associated with poor prognosis (P<0.05), suggesting its prominent role in LUAD. Tissue staining, Western blotting, and qRT-PCR demonstrated that SPRED1 was downregulated in LUAD tissues, and its low expression was significantly correlated with poor N stage and advanced pathological stage (P<0.05). Transwell, wound healing, and colony formation assays indicated that SPRED1 suppressed LUAD cell migration and proliferation. Furthermore, the CCK-8 assay confirmed that SPRED1 increases immunotherapeutic sensitivity.
Conclusions:
SPRED1 is downregulated in patients with LUAD and is an independent prognostic factor. SPRED1 enhances PD-L1 expression, thereby mediating its role in enhancing immunotherapeutic sensitivity in LUAD.
Insights
Sprouty-related EVH1 domain-containing 1 (SPRED1) is downregulated in lung adenocarcinoma (LUAD) and predicts poor prognosis. SPRED1 enhances programmed death-ligand 1 (PD-L1) expression, improving immunotherapy sensitivity in LUAD.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Biology
Background:
- Programmed death-ligand 1 (PD-L1) is a critical target in cancer immunotherapy.
- Sprouty-related EVH1 domain-containing 1 (SPRED1) negatively regulates the MAPK pathway and influences PD-L1 expression.
- SPRED1 exhibits antitumor properties across various cancer types.
Purpose of the Study:
- To investigate the role of SPRED1 in lung adenocarcinoma (LUAD) immunotherapy.
- To elucidate the mechanisms by which SPRED1 affects LUAD sensitivity to immunotherapy.
- To explore novel strategies for enhancing LUAD therapeutic responses.
Main Methods:
- Bioinformatic analysis of SPRED1 and LUAD patient prognosis.
- Quantitative assessment of SPRED1 expression using tissue staining, Western blotting, and qRT-PCR.
- Functional assays including CCK-8, colony formation, wound healing, and Transwell assays to evaluate LUAD cell behavior and immunotherapy response.
Main Results:
- SPRED1 expression is low in LUAD and correlates with poor prognosis, advanced N stage, and pathological stage.
- SPRED1 downregulation was confirmed in LUAD tissues.
- SPRED1 suppressed LUAD cell migration and proliferation, and enhanced sensitivity to immunotherapy.
Conclusions:
- SPRED1 is downregulated in LUAD and serves as an independent prognostic factor.
- SPRED1 enhances PD-L1 expression, thereby boosting immunotherapeutic sensitivity in LUAD.
More Related Videos
09:02Pre-Conditioning the Airways of Mice with Bleomycin Increases the Efficiency of Orthotopic Lung Cancer Cell Engraftment
Published on: June 28, 2018
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
